Chiang et al. demonstrated the beneficial effects of SGLT2 inhibitors in breast cancer patients treated with anthracyclines, with no increased risk of serious adverse events, such as hypoglycemia or sepsis [66]. The gene discussed is SLC5A2; the disease is breast carcinoma.